GlassScriptPhysician profile
Ashok Bhandari
NPI 1083671648
$2,426.67
in general payments reported to CMS, 2019-2025
18 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2021: $195 · 2022: $523 · 2023: $464 · 2024: $503 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,288 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.83 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $590.38 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $383.03 | 2019-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $272.45 | 2021-2024 | |
| Glaxosmithkline, LLC. | $265.93 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $182.51 | 2021-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $136.31 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $133.76 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $96.54 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $95.28 | 2019-2022 | |
| Astellas Pharma US INC | $77.61 | 2019-2023 | Veozah |
| Merck Sharp & Dohme LLC | $40.96 | 2019 | |
| Xeris Pharmaceuticals, INC. | $36.23 | 2024-2025 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $29.72 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.34 | 2023 | Jardiance |
| Abbvie INC. | $16.18 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $15.13 | 2019 | |
| Allergan, INC. | $14.20 | 2019 | |
| Daiichi Sankyo INC. | $14.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.